Literature DB >> 6507308

Assessment of the inotropic and vasodilator effects of amrinone versus isoproterenol.

B G Firth, A V Ratner, E D Grassman, M D Winniford, P Nicod, L D Hillis.   

Abstract

The hemodynamic effects of graded-dose infusions of amrinone (maximal dose 30 micrograms/kg/min) (10 patients) and isoproterenol (maximum dose 4 micrograms/min) (11 patients) were assessed in patients with a range of left ventricular (LV) function. LV ejection fraction ranged from 0.13 to 0.77 (mean +/- standard deviation 0.47 +/- 0.23) among the patients who received amrinone and from 0.24 to 0.77 (mean 0.52 +/- 0.18) among those who received isoproterenol. Peak-dose amrinone produced a reduction in LV filling pressure (from 15 +/- 10 to 10 +/- 7 mm Hg, p less than 0.001), but no significant change in heart rate, cardiac output, mean aortic pressure, total systemic vascular resistance (TSVR) or LV dP/dt max. In contrast, peak-dose isoproterenol produced a similar reduction in LV filling pressure (from 17 +/- 12 to 13 +/- 13 mm Hg, p less than 0.05), but also caused increases in heart rate, cardiac output and LV dP/dt max and decreases in mean aortic pressure and TSVR (p less than 0.001). The absolute change in cardiac output and stroke volume correlated closely with the change in TSVR in response to amrinone (r = -0.90, p less than 0.001 and r = -0.84, p = 0.002, respectively), but not in response to isoproterenol. Although isoproterenol produced a marked increase in cardiac output and LV dP/dt max (not explained by heart rate changes alone) in all patients, amrinone produced an increase in cardiac output only in those with markedly elevated LV filling pressures (who had a reduction in TSVR), and an increase in LV dP/dt in a minority.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6507308     DOI: 10.1016/s0002-9149(84)80092-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Noninvasive assessment of the inodilator action of amrinone in healthy man.

Authors:  C de Mey; D Enterling; G Hanft
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Haemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogs.

Authors:  A Dorszewski; B Müller-Beckmann; L Kling; G Sponer
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

Review 3.  Myocardial beta-adrenoceptor function and regulation in heart failure: implications for therapy.

Authors:  D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

4.  Alternative to the digitalis glycosides for heart failure.

Authors:  P Wilmshurst
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-18

Review 5.  Cardiovascular effects of forskolin and phosphodiesterase-III inhibitors.

Authors:  M Schlepper; J Thormann; V Mitrovic
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

6.  Effects of amrinone on cardiac contraction and relaxation in isolated, perfused rat heart.

Authors:  Y X Ma; H Y Zhao
Journal:  J Tongji Med Univ       Date:  1994

7.  Hemodynamic effects of amrinone in children after cardiac surgery.

Authors:  M Berner; C Jaccard; I Oberhansli; J C Rouge; B Friedli
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 8.  Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.

Authors:  T A Fischer; R Erbel; N Treese
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

Review 9.  Intravenous vasodilator therapy in congestive heart failure.

Authors:  Kourosh Moazemi; Jatinder S Chana; Anna Marie Willard; Abraham G Kocheril
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition.

Authors:  W S Colucci; A R Denniss; G F Leatherman; R J Quigg; P L Ludmer; J D Marsh; D F Gauthier
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.